Search

everythinglearnresearchcommunity

for

Search:↓

Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.

New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.

Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.

Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.

Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.

An 11-year-old girl with severe hair loss was successfully treated with a new combination therapy.

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.

New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.

JAK inhibitors may help treat alopecia areata by reversing hair loss.

Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

New treatments for Alopecia Areata show promise but need to be more effective and affordable.

JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.

A patient with complete hair loss regrew all her hair using tofacitinib.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

Upadacitinib may effectively treat alopecia areata without side effects.

An elderly Chinese man lost all his hair after taking a new heart medication.